Original Article

You have full text access to this OnlineOpen article

Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ

  1. Lei Huo MD, PhD1,
  2. Nour Sneige MD1,
  3. Kelly K. Hunt MD2,
  4. Constance T. Albarracin MD, PhD1,
  5. Adriana Lopez MS3,
  6. Erika Resetkova MD, PhD1,†,*

Article first published online: 14 SEP 2006

DOI: 10.1002/cncr.22216

Issue

Cancer

Cancer

Volume 107, Issue 8, pages 1760–1768, 15 October 2006

Additional Information

How to Cite

Huo, L., Sneige, N., Hunt, K. K., Albarracin, C. T., Lopez, A. and Resetkova, E. (2006), Predictors of invasion in patients with core-needle biopsy-diagnosed ductal carcinoma in situ and recommendations for a selective approach to sentinel lymph node biopsy in ductal carcinoma in situ. Cancer, 107: 1760–1768. doi: 10.1002/cncr.22216

Author Information

  1. 1

    Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  3. 3

    Department of Biostatistics and Applied Mathematics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas

  1. †

    Fax: (713) 563-1848.

*Department of Pathology, Unit 85, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030

Publication History

  1. Issue published online: 3 OCT 2006
  2. Article first published online: 14 SEP 2006
  3. Manuscript Accepted: 24 JUL 2006
  4. Manuscript Revised: 20 JUL 2006
  5. Manuscript Received: 21 APR 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (120K)

REFERENCES

  • 1
    Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000; 50: 7–33.
    Direct Link:
  • 2
    Ernster VL, Barclay J, Kerlikowske K, Grady D, Henderson C. Incidence of and treatment for ductal carcinoma in situ of the breast. JAMA. 1996; 275: 913–918.
  • 3
    Sneige N, Lim CS, Whitman GJ, et al. Atypical ductal hyperplasia diagnosis by directional vacuum-assisted stereotactic biopsy of breast microcalcifications. Consideration for surgical excision. Am J Clin Pathol. 2003; 119: 248–253.
  • 4
    Bagnall MJ, Evans AJ, Wilson AR, et al. Predicting invasion in mammographically detected microcalcification. Clin Radiol. 2001; 56: 828–832.
  • 5
    King TA, Farr GHJr., Cederbom GJ, et al. A mass on breast imaging predicts coexisting invasive carcinoma in patients with a core biopsy diagnosis of ductal carcinoma in situ. Am Surg. 2001; 67: 907–912.
  • 6
    Cox CE, Nguyen K, Gray RJ, et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg. 2001; 67: 513–519.
  • 7
    Hoorntje LE, Schipper ME, Peeters PH, Bellot F, Storm RK, Borel Rinkes IH. The finding of invasive cancer after a preoperative diagnosis of ductal carcinoma-in-situ: causes of ductal carcinoma-in-situ underestimates with stereotactic 14-gauge needle biopsy. Ann Surg Oncol. 2003; 10: 748–753.
  • 8
    Lee CH, Carter D, Philpotts LE, et al. Ductal carcinoma in situ diagnosed with stereotactic core needle biopsy: can invasion be predicted? Radiology. 2000; 217: 466–470.
  • 9
    Verkooijen HM, Peeters PH, Buskens E, et al. Diagnostic accuracy of large-core needle biopsy for nonpalpable breast disease: a meta-analysis. Br J Cancer. 2000; 82: 1017–1021.
  • 10
    Jackman RJ, Burbank F, Parker SH, et al. Stereotactic breast biopsy of nonpalpable lesions: determinants of ductal carcinoma in situ underestimation rates. Radiology. 2001; 218: 497–502.
  • 11
    Yen TW, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005; 200: 516–526.
  • 12
    Renshaw AA. Predicting invasion in the excision specimen from breast core needle biopsy specimens with only ductal carcinoma in situ. Arch Path Lab Med. 2002; 126: 39–41.
  • 13
    Schwartz GF, Giuliano AE, Veronesi U. Consensus Conference Committee. Proceedings of the Consensus Conference on the Role of Sentinel Lymph Node Biopsy in Carcinoma of the Breast, April 19–22, 2001, Philadelphia, Pennsylvania. Cancer. 2002; 94: 2542–2551.
    Direct Link:
  • 14
    Klauber-DeMore N, Tan LK, Liberman L, et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in-situ and ductal carcinoma-in-situ with microinvasion? Ann Surg Oncol. 2000; 7: 636–642.
  • 15
    Intra M, Veronesi P, Mazzarol G, et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg. 2003; 138: 309–313.
  • 16
    Pendas S, Dauway E, Giuliano R, Ku N, Cox CE, Reintgen DS. Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol. 2000; 7: 15–20.
  • 17
    Hosmer DW, Lemeshow S. Applied Logistic Regression. 2nd ed. Hoboken, NJ: John Wiley & Sons, Inc.; 2000.
  • 18
    Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999; 353: 1993–2000.
  • 19
    Lagios MD. Duct carcinoma in situ. Pathology and treatment. Surg Clin North Am. 1990; 70: 853–871.
  • 20
    Lee KS, Han BH, Chun YK, Kim HS, Kim EE. Correlation between mammographic manifestations and averaged histopathologic nuclear grade using prognosis-predict scoring system for the prognosis of ductal carcinoma in situ. Clin Imaging. 1999; 23: 339–346.
  • 21
    Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet. 1995; 345: 1154–1157.
  • 22
    Fisher ER, Costantino J, Fisher B, Palekar AS, Redmond C, Mamounas E. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) Protocol B-17. Intraductal carcinoma (ductal carcinoma in situ). The National Surgical Adjuvant Breast and Bowel Project Collaborating Investigators. Cancer. 1995; 75: 1310–1319.
    Direct Link:
  • 23
    Holland R, Hendriks JH, Vebeek AL, Mravunac M, Schuurmans Stekhoven JH. Extent, distribution, and mammographic/histological correlations of breast ductal carcinoma in situ. Lancet. 1990; 335: 519–522.
  • 24
    Azzopardi JG, Laurini RN. Elastosis in breast cancer. Cancer. 1974; 33: 174–183.
    Direct Link:
  • 25
    Fisher ER, Sass R, Fisher B, Wickerham L, Paik SM. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 6). I. Intraductal carcinoma (DCIS). Cancer. 1986; 57: 197–208.
    Direct Link:
  • 26
    Goldstein NS, Kestin L, Vicini F. Pathologic features of initial biopsy specimens associated with residual intraductal carcinoma on reexcision in patients with ductal carcinoma in situ of the breast referred for breast-conserving therapy. Am J Surg Pathol. 1999; 23: 1340–1348.
  • 27
    Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for T1a breast carcinoma. Is it indicated? Cancer. 1994; 73: 664–667.
    Direct Link:
  • 28
    Lara JF, Young SM, Velilla RE, Santoro EJ, Templeton SF. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer. 2003; 98: 2105–2113.
    Direct Link:
  • 29
    Strickland AH, Beechey-Newman N, Steer CB, Harper PG. Sentinel node biopsy: an in depth appraisal. Crit Rev Oncol Hematol. 2002; 44: 45–70.
  • 30
    Kelemen PR. Comprehensive review of sentinel lymphadenectomy in breast cancer. Clin Breast Cancer. 2000; 1: 111–125.
  • 31
    Hill AD, Tran KN, Akhurst T, et al. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg. 1999; 229: 528–535.
  • 32
    Lagios MD, Westdahl PR, Margolin FR, Rose MR. Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short-term treatment failures. Cancer. 1982; 50: 1309–1314.
    Direct Link:
View Full Article (HTML) Get PDF (120K)